Minimal decreases in plasma aldosterone were observed after administration of valsartan. In the former, there was a better prognosis (vs. placebo) when valsartan was combined with prior ACE inhibitor therapy. In contrast to CHARM-Added, the triple combination of an ARB, an ACE diovan 80 mg cost inhibitor, and a β-blocker was detrimental. However, this was a post-hoc analysis, whereas CHARM was prospective and a larger series. It is, however, now also approved for reduction of cardiovascular mortality in clinically stable patients with LV failure or LV dysfunction.